Table 8.
Preliminary estimates of the clinical utility of testing metastatic CRC patients for UGT1A1 polymorphisms: Benefits and harms among UGT1A1*28 homozygotes
| Effectiveness of irinotecan dose reduction in preventing neutropenia (%) | Projected Total number of neutropenia cases | Cases of neutropenia avoided | Number needed to test to avoid one case of neutropenia | Additional nonresponsive CRC tumors: case of neutropenia avoided |
|---|---|---|---|---|
| 100 | 219 | 548 | 36 | 1.2:1 |
| 90 | 274 | 493 | 41 | 1.3:1 |
| 80 | 328 | 439 | 46 | 1.5:1 |
| 70 | 383 | 384 | 52 | 1.7:1 |
| 60 | 438 | 329 | 61 | 2.0:1 |
| 50 | 493 | 274 | 73 | 2.4:1 |
| 40 | 548 | 219 | 91 | 2.9:1 |
| 30 | 603 | 164 | 122 | 3.9:1 |
| 20 | 658 | 109 | 183 | 5.9:1 |
| 10 | 713 | 54 | 370 | 12:1 |